MEDLAB has commenced a safety study for oncology patients undergoing chemotherapy using its Multibiotic nutraceutical product.
The phase 1 trial at the Northern Cancer Institute in St Leonards, NSW, will focus on safety and tolerability in reducing intestinal inflammatory ulcerations.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 18